Zbigniew Zdrojewski


Antineutrophil cytoplasmic antibody­‍‑associated vasculitis (AAV) is a group of systemic diseases characterized by necrotizing inflammation of small and medium size vessels, without immunologic deposits, and with the presence of specific serum antibodies. Recent genetic and cohort studies should improve the comprehension of the pathogenesis of AAV, the stratification of patients into homogenous groups, and lead to therapeutic implications. Immunosuppressive therapy of AAV includes two major periods: induction of remission and maintenance therapy. Therapy should be chosen individually, not only depending on the stage and severity of the disease, but also on genetic and some prognostic factors. Previous randomized trials and clinical observations show some possible limitations of treatment with cyclophosphamide and steroids. Rytuximab seems to be a good alternative in those patients in induction therapy as well as in maintenance therapy.


antineutrophil cytoplasmic antibody‑associated vasculitis; granulomatosis with polyangiitis; microscopic polyangiitis; individualisation of the treatment

Full Text:

PDF (Język Polski)


Jannette J., Falk R., Bacon P., Basu N., Cid M.C., Ferrario F. et al.: Revised international Chapel Hill consensus conference nomenclature of vasculitis. Arthritis Rheum. 2012, 65, 1–11.

Mahr A., Katsahian S., Vavet H., Gullevin L., Hagen E.Ch., Hoglund P. et al.: Revisiting the classification of clinical phenotypes of antineutrophil cytoplasmic antibody‑associated vasculitis: a cluster analysis. Ann Rheum Dis. 2013, 72, 1003–1010.

Lyons P.A., Rayner T.F., Trivedi S., Holle J.U., Watts R., Jayne D.R.W. et al.: Genetically distinct subsets within ANCA‑associated vasculitis. N Engl J Med. 2012, 367, 214–223.

Furuta S., Jayne D.R.W.: Antineutrophil cytoplasm antibody‑associated vasculitis: recent developments. Kidney Int. 2013, 84, 244–249.

de Jode A.A.E., Sanders J.S.F., Stegeman C.A: Renal survival in proteinase 3 and myeloperoxidase ANCA‑associated systemic vasculitis. Clin J Am Soc Nephrol. 2013, 8, 1709–1717.

Berden A.E., Ferrario F., Hagen E.C.: Histologic classification of ANCA‑associated glomerulonephritis. J Am Soc Nephrol. 2010, 21, 1628–1636.

Berden A.E., Jones R.B., Erasmus D.D.: Tubular lessons predict renal outcome in antineutrophilcytoplasmatic antibody‑associated glomerulonephritis after rituximab therapy. J Am Soc Nephrol. 2012, 23, 313–321.

Harper L., Morgan M.D., Walsh M., Jayne D.R.W., de Groot K., Grego‑ rini G. et al.: Pulse versus daily oral cyclophosphamide for induction in ANCA‑associated vasculitis: long‑term follow‑up. Ann Rheum Dis. 2012, 71, 955–960.

Mansfield N., Hamour S., Habib A.M., Tarzi R., Levy J., Griffith M. et al.: Prolonged disease – free remission following rituximab and low‑dose cyclophosphamide therapy for renal ANCA: associated vasculitis. Nephrol Dial Transplant. 2011, 26, 3280–3286.

Faurschon M., Westman K., Rasmussen N.: Long‑term outcome of a clinical trial comparing metothrexate to cyclophosphamide for remission induction of early systemic ANCA‑associated vasculitis. Arthritis Rheum. 2012, 64, 3472–3477.

Zdrojewski Z.: Mycophenolate mofetil for treatment of vasculitis. Forum Nefrol. 2013, 6, 55–62.

Alberici F., Jayne D.R.W.: Impact of rituximab trials on the treatment of ANCA‑associated vasculitis. Nephrol Dial Transplant. 2013, 1, 1–12.

Jones R.B., Tervaret J.W.C., Hauser T., Luqmani R., Morgan M.D., Peh C.A. et al.: Rituximab versus cyclophosphamide in ANCA Associated Renal Vasculitis. N Engl J Med. 2010, 363, 211–220.

Stone J.H., Merkel P.A., Spiera R., Seo Ph., Langford C.A., Hoffman G.S. et al.: Rituximab versus cyclophosphamide for ANCA‑associated vasculitis. N Engl J Med. 2010, 363, 221–232.

Specks U., Merkel P.A., Seo Ph., Spiera R., Langford C.A., Hoffman G.S. et al.: Efficacy of Remission – Induction regimens for ANCA‑associated vasculitis. N Engl J Med. 2013, 369, 417–427.

Walsh M., Merkel P.A. Mahr A., Berden A., Westman K., Stegman C. et al.: Effects of glucocorticoid therapy on relapse rate in antineuthrophil cytoplasmic antibody‑associated vasculitis. A meta‑analysis. Arthritis Care Res. 2010, 62, 1166–1173.

Jayne D.R.W., Gaskin G., Rasmussen N., Rasmussen N., Abramowicz D., Ferrario F. et al.: Randomized trial of plasma exchange or high‑dosage methylprednisolone as adjunctive therapy for severe renal vasculitis. J Am Soc Nephrol. 2007, 18, 2180–2188.

Walsh M., Casian A., Flossmann O., Westman K., Hoglund P., Pusey Ch. et al.: Long‑term follow‑up of patients with severe ANCA‑associated vasculitis comparing plasma exchange to intravenous methylprednisolone, treatment is uncler. Kidney Int. 2013, 84, 397–402.

Pepper R.J., Chanouzas D., Tarzi R., Little M.A., Casian A., Walsh M. et al.: Intravenous cyclophosphamide and plasmapheresis in dialysis – dependent ANCA‑associated vasculitis. Clin J Am Soc. Nephrol. 2013, 8, 219–2013.

Walsh M., Merkel P.A., Peh Ch.A., Szpirt W., Gullevin L., Pusey Ch.D. et al.: Plasma exchange and glucocorticoid dosing in the treatment of anti‑neutrophil cytoplasm antibody associated vasculitis (PEXIVAS): protocol for randomized controlled trial. content/14/1/73.

Laurino S., Chandhry A., Booth A.: Prospective study of TNF blockade with adalimumab in antineutrophil cytoplasmic antibody‑associated systemic vasculitis with renal involvement. Nephrol Dial Transplant. 2010, 25, 3307–3314.

Pagnoux C., Mahr A., Hamidon M.A.: Azathioprine or methotrexate maintenance for ANCA‑associated vasculitis. N Engl J Med. 2008, 359, 2790–2803.

Metzler C., Miehle N., Maugler K.: Elevated relapse rate under oral methotrexate versus leflunomide for maintenance of remission in Wegener’s granulomatosis. Rheumatology. 2007, 46, 1087–1091.

Hiemstra T.F., Walsh M., Mahr A., Savage C.O., de Groot K., Harper L. et al.: Mycophenolatemofetil vs azathioprine for remission maintenance in anti‑neutrophil cytoplasmic antibody associated vasculitis: a randomized controlled trial. JAMA. 2010, 304, 2381–2388.

Smith R.M., Jones R.B., Guerry M.J., Laurino S., Catapano F., Chau‑ dhry A. et al.: Rituximab for remission maintenance in relapsing antineutrophil cytoplasmic antibody‑associated vasculitis. Arthritis Rheum. 2012, 64, 3760–3769.

Flossmann O., Berden A., de Groot K., Hagen C., Harper L., Heijl C. et al.: Long‑term patient survival in ANCA‑associated vasculitis. Ann Rheum Dis. 2011, 70, 488–494.

Walsh M., Flossmann O., Berden A., Westman K., Hoglund P., Stege‑ man C. et al.: Risk factors for relapse of antineutrophil cytoplasmic antibody‑associated vasculitis. Arthritis Rheum. 2012, 64, 542–548.


Copyright (c) 2016 Zbigniew Zdrojewski

License URL: